TORC News and Press, resTORbio Inc. From 03/18/19

BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has commenc...

resTORbio (NASDAQ: TORC ): Q4 GAAP EPS of -$0.21 beats by $0.13 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson’s disease (PD) expected to initiate in 1Q19 BOSTON, March 18, 2019 ...

ResTORbio ( TORC +2.3% ) is on go to launch two Phase 3 clinical trials evaluating lead candidate RTB101 for preventing respiratory tract infections (RTIs) in the elderly. More news on: resTORbio, Inc., Healthcare stocks news, Read more ...

Phase 3 program on track to start enrolling patients in the second quarter of 2019 Data from two Phase 2 clinical trials enrolling more than 900 patients support the design of the Phase 3 program BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-s...

BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced that company management will present a corporat...

BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced the appointment of Erkan Baloglu, Ph.D., M.B.A.,...

BOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced it will host a key opinion leader (KOL) symposiu...

88 companies went public in 2018 with venture capital backing. Excluding Spotify's (SPOT) direct listing, the group raised $15 billion in the IPO market. Venture exits accounted for 46% of 2018's total, and VC deal count and proceeds reached a 4-year high. The pickup in activity was driven by ...

BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announc...